FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

The U.S. Food and Drug Administration (FDA) approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to sever opioid use disorder (OUD). Buprenorphine is a safe and effective medication for OUD treatment. The FDA's priorities in their Overdose Prevention Framework are supporting primary prevention, encouraging harm reduction, advancing development of evidence-based treatments, and protecting the public from substances.